

Inscripta and The Onyx Platform

Cell Factories For Bioproduction 29-MAR-2022


Laura Klitten, PhD. Scientific Liaison

Laura.klitten@inscripta.com



Inscripta offers transformational solutions for genome engineering

Easy access to gene editing



- License MAD7 nuclease
- Collaborate for access to nuclease panels

Genome-scale engineering



- Purchase the First Benchtop Platform for Digital Genome Engineering

End to End project collaboration



- Partner with the best talent in genome-engineering

Rapid genome-scale engineering with the Onyx[®] platform

Access

- **Nuclease:** MAD7
- **Hosts:** *E. coli* and *S. cerevisiae*
- **Strains:** Inscripta standard strains and related customer strains
- **Genome targets:**
 - Coding and non-coding regions in the native genome
 - Heterologous sequences introduced in the genome

Scale

- **Designs per library:**
 - *E. coli*: 100 – 10,000
 - *S. cerevisiae*: 100 - 6000

Performance

- **Precision:** 1 Edit per cell
- **Diversity:** Insertions, deletions and substitutions (1-63 bps)
- **Library Composition:** >90% designs covered with 15-75% edited cells
- **Time:**
 - Reagent delivery – ~3 weeks and Library build – 2-4 days
 - Hands on time: 30 mins


The Onyx[®] Platform supports all areas of the DGTL cycle

Easy-to-use web portal for design and order of editing libraries



Software for analyzing experimental results

Design



Generate



Learn



Test



Automated CRISPR-based HTP genome editing



Genotyping kits and analysis software, customer screening workflows



Inscripta's mission is to enable researchers to realize the full potential of biology

History



- Founded in 2015
- Private company with offices in Boulder, Pleasanton, San Diego and Copenhagen
- Seasoned leadership and notable blue-chip investors: *Fidelity, TRowe Price, Morgan Stanley Asset Management*

Key Accomplishments

- Validated chemistry (*in bacteria and yeast*)
- Publications include *Nature Biotechnology* and *Cell Systems*
- Patented Editing Systems with Novel CRISPR Nucleases (MADzyme™ Nucleases)
- First Commercial Shipment of the Onyx Platform in 2021

Offering

- Solutions supported by large and growing patent portfolio
- Key customer applications include:
 - Genome Discovery
 - Forward Engineering



Forbes

The World's First Fully Automated Benchtop Digital Genome Engineering Platform Is Here

April 28, 2021

As synthetic biology continues to grow, advanced benchtop systems are becoming available to make research and product development easier. Now...

[READ MORE >](#)



Thank you!

inscripta.com

Copyright © 2022 Inscripta, Inc. For Research Use Only.
Not for use in diagnostic procedures.
Inscripta, Onyx and the Inscripta logo are all trademarks of Inscripta, Inc. in the United States and/or other countries.



INSCRIPTA[®]
The Digital Genome Engineering Company